



INFORMAZIONI PERSONALI	
Cognome e nome	SPADA FRANCESCA
Nazionalità	Italiana
Data di nascita	06/11/1977
Sede professionale attuale	Istituto Europeo di Oncologia via Giuseppe Ripamonti, 20141 Milano (MI), Italia
E-mail	francesca.spada@ieo.it
CF	SPDFNC77S46G113A

ESPERIENZE PROFESSIONALI	
	Medico oncologo con esperienza di oltre 15 anni nell'attività clinica e di ricerca clinica sui tumori del tratto gastrointestinale e sulle neoplasie neuroendocrine, in accordo alle norme di buona pratica clinica (GCP). Luglio 2023 – in corso Istituto Europeo di Oncologia, IEO, IRCCS, via G. Ripamonti 435, 20141 Milano. Divisione di Oncologia Medica Gastrointestinale e Tumori Neuroendocrini Qualifica: medico oncologo con Incarico di Alta Specializzazione per le Neoplasie Neuroendocrine a contratto indeterminato Ottobre 2017 – luglio 2023 Istituto Europeo di Oncologia, IEO, IRCCS, via G. Ripamonti 435, 20141 Milano. Divisione di Oncologia Medica Gastrointestinale e Tumori Neuroendocrini Qualifica: medico oncologo con contratto a tempo indeterminato Gennaio 2016 – settembre 2017 Istituto Europeo di Oncologia, IEO, IRCCS, via G. Ripamonti 435, 20141 Milano. Unità di Oncologia Medica Gastrointestinale e Tumori Neuroendocrini Qualifica: medico oncologo con contratto a tempo indeterminato Agosto 2011 – dicembre 2015 Istituto Europeo di Oncologia, IEO, IRCCS, via G. Ripamonti 435, 20141 Milano. Unità di Oncologia Medica Gastrointestinale e Tumori Neuroendocrini Qualifica: medico oncologo a contratto determinato con borsa di studio. Luglio 2007 - luglio 2011 Azienda Ospedaliero-Universitaria, Oncologia Universitaria, viale San Pietro 8, 20141, Sassari. Scuola di Specializzazione in Oncologia Medica.



	Qualifica: medico specializzando. Febbraio 2009 - marzo 2010 Istituto Europeo di Oncologia, via Ripamonti 435, 20141 Milano. Divisione di Oncologia Medica. Qualifica: medico specializzando frequentatore in oncologia medica Luglio 2005 - settembre 2010 Azienda Sanitaria Locale N.2, Olbia Azienda Sanitaria Locale N.5, Oristano Qualifica: medico a tempo determinato di guardia medica e turistica. Febbraio 2007 - giugno 2007 Azienda Ospedaliero-Universitaria, Oncologia Universitaria, viale San Pietro 8, 20141, Sassari Qualifica: medico frequentatore laureato ed abilitato all'esercizio della professione medica coinvolto nell'attività clinica e di ricerca clinica sui tumori della mammella, del polmone, del tratto urogenitale, del tratto gastrointestinale e sui tumori neuroendocrini, in accordo alle norme di buona pratica clinica (GCP) Ottobre 2005 – gennaio 2007 Ospedale “A. Businco”, ASL N.8, Via Jenner, 09125 Cagliari Qualifica: medico frequentatore laureato ed abilitato all'esercizio della professione medica coinvolto nell'attività clinica e di ricerca clinica sui tumori della mammella, del polmone, del tratto urogenitale, del tratto gastrointestinale e sui tumori neuroendocrini, in accordo alle norme di buona pratica clinica (GCP)
--	---

FORMAZIONE	
	Dicembre 2023 Abilitazione Scientifica Nazionale alle Funzioni di Professore Universitario di II Fascia nel Settore Concorsuale 06/D3 Malattie del Sangue, Oncologia, Reumatologia. Aprile 2018 – dicembre 2018 The Christie NHS Foundation Trust, Manchester (UK). Periodo formativo di ricerca clinica sulle neoplasie neuroendocrine e del tratto epato-bilio-pancreatico e sulle neoplasie neuroendocrine con particolare attenzione alla chemioterapia nel trattamento delle neoplasie neuroendocrine di alto grado extra-polmonari e alle metastasi ossee da neoplasie neuroendocrine. Ottobre 2015 – ottobre 2018 Dottorato in Medicina Sperimentale e Traslazionale Università dell'“Insubria”, Facoltà di Medicina e Chirurgia. Università degli Studi di Varese, Italia Luglio 2011 Specializzazione in Oncologia Medica, 50/50 e lode, Università degli Studi di Sassari, Italia Facoltà di Oncologia Medica



CURRICULUM VITAE

	Marzo 2005 Università degli Studi di Cagliari, Italia Abilitazione all'esercizio professionale Agosto 2004 Corso di lingua inglese CL English School, Londra, 170 Westminster Bridge Road, SE1 7 RW Qualifica: qualificato (livello intermedio) 24/07/2004 Laurea in Medicina e Chirurgia, punteggio 110/110 Università degli Studi di Cagliari, Italia 1996-2004 Corso di Studi in Medicina e Chirurgia Università degli Studi di Cagliari Settembre 1991- Luglio 1996 Diploma di Scuola media Superiore, Liceo Classico "S.A. De Castro" Oristano Qualifica: promossa, votazione 60/60
--	---

CARATTERISTICHE PERSONALI	
MADRELINGUA	Italiana
ALTRE LINGUE:	INGLESE Lettura: fluente Scrittura: Ottimo Scrittura: fluente
UTILIZZO DEL PERSONAL COMPUTER	Buona conoscenza ed uso dei Sistemi operativi: macOS, Windows 10, 7, XP e Windows Vista. Buona conoscenza ed uso di Microsoft Office (Word, Excel, Power Point and Access). Buona conoscenza ed uso di Internet Explorer. Buona conoscenza ed uso di Electronic Mail.
PATENTE DI GUIDA	Patente B. Dotata di autovettura propria. Disponibile agli spostamenti / trasferimenti in Italia o all'Estero.



ULTERIORI INFORMAZIONI	Coordinatrice di Qualità del Centro di Eccellenza ENETS per le Neoplasie Neuroendocrine presso l'Istituto Europeo di Oncologia, IEO, IRCCS, Milano. Esperienze in Studi Clinici di fase II, III and IV in accordo alle buone norme di pratica clinica: NIAID GCP (training effettuato ad agosto 2011). Membro del Comitato Scientifico della Società Italiana dei Tumori Neuroendocrini (Itanet), periodo 2021-ongoing. Membro del Direttivo della Società Italiana dei Tumori Neuroendocrini (Itanet), periodo 2018-2021. Membro del Direttivo del gruppo giovani dell'Associazione Italiana di Oncologia Medica (AIOM) negli anni 2017-2019. Membro delle seguenti società scientifiche: - Associazione Italiana di Oncologia Medica (AIOM) - North American Neuro-Endocrine Tumor Society (NANETS) - European Society of Medical Oncology (ESMO) - European Neuroendocrine Tumor Society (ENETS) - Italian Neuroendocrine Tumor Society (ITANET) Coordinatrice delle Linee Guida italiane AIOM in collaborazione con ITANET dall'anno 2020 - ongoing Segretario scientifico delle Linee Guida italiane, AIOM n collaborazione con ITANET negli anni 2013/2014/2015/2016/2017/2018. Coordinatrice Task Force Linee Guida Neoplasie Neuroendocrine ITANET dal 2018-ongoing Partecipante a più di 300 congressi scientifici nazionali ed internazionali come relatore e discente sulle neoplasie neuroendocrine.
-------------------------------	--

**Elenco delle pubblicazioni scientifiche:**

1. **Gender perspective in Lung Neuroendocrine Tumors: a critical review.** La Salvia A, Modica R, **Spada F**, Rossi RE. *Neuroendocrinology* 2025 Apr 24;1-14. doi: 10.1159/000546081.
2. **Molecular tumour board in gastrointestinal cancers.** Boscolo Bielo L, Crimini E, Repetto M, Barberis M, Battaiotto E, Katrini J, Martino E, Gaudio G, Lombardi M, Zanzottera C, Aurilio G, Belli C, Zhan Y, Fuorivia V, Marsicano RM, Etessami JD, Zagami P, Marra A, Trapani D, Taurelli Salimbeni B, Criscitiello C, Ciardiello D, Lavinia B, Gervaso L, Cella CA, **Spada F**, Zampino MG, Fusco N, Fazio N, Guerini Rocco E, Curigliano G. *ESMO Open*. 2025 Mar 19;10(4):104510. doi: 10.1016/j.esmoop.2025.104510.
3. **Functioning neuroendocrine tumors (NET): Minimum requirements for a NET specialist.** **Spada F**, Rossi RE, Modica R, Gelsomino F, Rinzivillo M, Rubino M, Pisa E, Salvia A, Fazio N. *Cancer Treat Rev*. 2025 Feb 27;135:102907. doi: 10.1016/j.ctrv.2025.102907.
4. **Raising the bar: evaluating quality and consistency in clinical guidelines for surgical management of pulmonary carcinoid.** Bertolaccini L, Bardoni C, Caffarena G, Chiari M, Diotti C, Mazzella A, Benini L, **Spada F**, Corso G, Pisa E, Casiraghi M, Fazio N, Spaggiari L. *Eur J Cancer Prev*. 2025 Jan 7. doi: 10.1097/CEJ.0000000000000949.
5. **Gender impact on pancreatic neuroendocrine neoplasm (PanNEN) prognosis according to survival nomograms.** La Salvia A, Modica R, **Spada F**, Rossi RE. *Endocrine*. 2025 Apr;88(1):14-23. doi: 10.1007/s12020-024-04129-z. Epub 2024 Dec 13.
6. **Surgical and Oncologic Outcomes of Primary Tumor Resection in Patients with Small Intestinal Neuroendocrine Tumors: Results from a Single-Center Series Over a 15-Year Period.** La Salvia A, Modica R, **Spada F**, Rossi RE. *Endocrine*. 2024 Dec 13. doi: 10.1007/s12020-024-04129-z. Online ahead of print. PMID: 39671148 Review.
7. **Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers.** Algeri L, Falkman L, **Spada F**, Frassoni S, Bagnardi V, Boselli S, Cardinale D, Zanobini M, Crona J, Benini L, Tamayo D, Mazzon C, Gervaso L, Cella CA, Zampino MG, Ciardiello D, Russo A, Badalamenti G, Welin S, Fazio N. *ESMO Open*. 2024 Nov;9(11):103959. doi: 10.1016/j.esmoop.2024.103959. Epub 2024 Oct 22. PMID: 39442478
8. **The Role of Liquid Biopsy in Gastroenteropancreatic Neuroendocrine Neoplasms.** Almeida C, Gervaso L, Frigè G, **Spada F**, Benini L, Cella CA, Mazzarella L, Fazio N. *Cancers (Basel)*. 2024 Sep 30;16(19):3349. doi: 10.3390/cancers16193349. PMID: 39409968
9. **Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study.** Mortier L, Villabona L, Lawrence B, Arance A, Butler MO, Beylot-Barry M, Saiag P, Samimi M, Ascierto PA, **Spada F**, De Pontville M, Maio M, Berrocal A, Espinosa E, Capdevila J, Levin M, Das D, Krepler C, Grebennik D,



Chiarion-Sileni V. *Am J Clin Dermatol*. 2024 Nov;25(6):987-996. doi: 10.1007/s40257-024-00885-w. Epub 2024 Oct 8. PMID: 39377880.

10. **Gastric neuroendocrine tumors: 20-Year experience in a reference center.** Ravizza D, Giunta M, Sala I, Bagnardi V, Tamayo D, de Roberto G, Trovato C, Bravi I, Soru P, Maregatti M, Pisa E, Bertani E, Bonomo G, **Spada F**, Nicola F. *J Neuroendocrinol*. 2024 Dec;36(12):e13440. doi: 10.1111/jne.13440. Epub 2024 Aug 27. PMID: 39191460
11. **Pneumonectomy for broncho-pulmonary carcinoids: a single centre analysis of surgical approaches and patient outcomes.** Diotti C, Bertolaccini L, Girelli L, Uslenghi C, Donghi SM, Guarize J, **Spada F**, Fazio N, Spaggiari L. *Front Oncol*. 2024 Jul 24;14:1383352. doi: 10.3389/fonc.2024.1383352. eCollection 2024. PMID: 39114309.
12. **Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study.** Guidi L, Valenza C, Battaiotto E, Trapani D, Ghioni MC, Crimini E, Boscolo Bielo L, Venetis K, Belli C, Bottiglieri L, Gervaso L, Cella CA, Ciardiello D, **Spada F**, Benini L, Adorisio R, Mane E, Fazio N, Guerini Rocco E, Curigliano G, Zampino MG. *ESMO Open*. 2024 Aug;9(8):103662. doi: 10.1016/j.esmoop.2024.103662. Epub 2024 Aug 6. PMID: 39111110.
13. **Immunotherapy in Neuroendocrine Neoplasms: A Diamond to Cut.** García-Torralba E, Garcia-Lorenzo E, Doger B, **Spada F**, Lamarca A. *Cancers (Basel)*. 2024 Jul 13;16(14):2530. doi: 10.3390/cancers16142530. PMID: 39061170.
14. **A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas.** Bongiovanni A, Liverani C, Foca F, Bergamo F, Leo S, Pusceddu S, Gelsomino F, Brizzi MP, Di Meglio G, **Spada F**, Tamberi S, Lolli I, Cives M, Marconcini R, Pucci F, Berardi R, Antonuzzo L, Badalamenti G, Santini D, Recine F, Vanni S, Tebaldi M, Severi S, Rudnas B, Nanni O, Ranallo N, Crudi L, Calabrò L, Ibrahim T. *Eur J Cancer*. 2024 Sep;208:114129. doi: 10.1016/j.ejca.2024.114129. Epub 2024 May 25. PMID: 39002347
15. **Circulating tumor DNA in patients with locally advanced rectal cancer treated with multimodal treatment.** Gervaso L, Ciardiello D, Gregato G, Guidi L, Valenza C, Ascione L, Boldrini L, Frassoni S, Cella CA, **Spada F**, Funicelli L, De Roberto G, Petz W, Borin S, Gerardi MA, Bottiglieri L, Tamayo D, Bertani E, Fumagalli Romario U, Bagnardi V, Curigliano G, Bertolini F, Fazio N, Zampino MG. *Ther Adv Med Oncol*. 2024 Jun 13;16:17588359241249602. doi: 10.1177/17588359241249602. eCollection 2024.
16. **Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe?** Gervaso L, Ciardiello D, Oliveira RA, Borghesani M, Guidi L, Benini L, Algeri L, **Spada F**, Zampino MG, Cella CA, Fazio N. *J Immunother Cancer*. 2024 May 23;12(5):e008027. doi: 10.1136/jitc-2023-008027.
17. **Venous thromboembolism in pancreatic neuroendocrine neoplasm: a cohort study.** Gervaso L, Laffi A, Gaeta A, Gandini S, Boldrini L, Meneses-Medina MI, Rubino M, Benini L, Borghesani M, Algeri L, Curigliano G, **Spada F**, Cella CA, Fazio N. *Res Pract Thromb Haemost*. 2024 Mar 15;8(3):102381. doi: 10.1016/j.rpth.2024.102381. eCollection 2024 Mar.
18. **Authorship of Italian medical literature on neuroendocrine neoplasms: any gender gap?** Rossi RE, La Salvia A, Modica R, **Spada F**. *J Endocrinol Invest*. 2024 Oct;47(10):2587-2593. doi: 10.1007/s40618-024-02347-w. Epub 2024 Mar 28



19. **An Italian real-world multicenter study of patients with advanced mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs) of the gastro-entero-pancreatic system treated with chemotherapy.** Spada F, Milione M, Maisonneuve P, Prinzi N, Smioldo V, Bolzacchini E, Pusceddu S, Carnaghi C, Sessa F, La Rosa S, Uccella S, Fazio N. *J Endocrinol Invest.* 2024 Sep;47(9):2279-2294. doi: 10.1007/s40618-024-02314-5. Epub 2024 Feb 24.
20. **Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database.** Panzuto F, Partelli S, Campana D, de Braud F, Spada F, Cives M, Tafuto S, Bertuzzi A, Gelsomino F, Bergamo F, Marcucci S, Mastrangelo L, Massironi S, Appetecchia M, Filice A, Badalamenti G, Bartolomei M, Amoroso V, Landoni L, Rodriquez MG, Valente M, Colao A, Isidori A, Fanciulli G, Bollina R, Ciola M, Butturini G, Marconcini R, Arvat E, Cinieri S, Berardi R, Baldari S, Riccardi F, Spoto C, Giuffrida D, Gattuso D, Ferone D, Rinzivillo M, Bertani E, Versari A, Zerbi A, Lamberti G, Lauricella E, Pusceddu S, Fazio N, Dell'Unto E, Marini M, Falconi M. *Endocrine.* 2024 Apr;84(1):42-47. doi: 10.1007/s12020-023-03649-4. Epub 2024 Jan 4.
21. **Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survival.** La Salvia A, Lens-Pardo A, López-López A, Carretero-Puche C, Capdevila J, Benavent M, Jiménez-Fonseca P, Castellano D, Alonso T, Teule A, Custodio A, Tafuto S, La Casta A, Spada F, Lopez-Gonzalez A, Gil-Calderon B, Espinosa-Olarte P, Barbas C, Garcia-Carbonero R, Soldevilla B. *Eur J Endocrinol.* 2024 Jan 3;190(1):62-74. doi: 10.1093/ajendo/lvad160.
22. **Promising targetable biomarkers in pancreatic neuroendocrine tumours.** Borghesani M, Gervaso L, Cella CA, Benini L, Ciardiello D, Algeri L, Ferrero A, Valenza C, Guidi L, Zampino MG, Spada F, Fazio N. *Expert Rev Endocrinol Metab.* 2023 Sep-Nov;18(5):387-398. doi: 10.1080/17446651.2023.2248239.
23. **Digestive MiNENs: Could histological classification and molecular characterization drive clinical outcome and therapeutic approach?** Cattaneo L, Centonze G, Sabella G, Lagano V, Angerilli V, Pardo C, Bertani E, Spada F, Prinzi N, Pusceddu S, Fassan M, Fazio N, Milione M. *Crit Rev Oncol Hematol.* 2023 Jun 1;188:104044. doi: 10.1016/j.critrevonc.2023.104044. Online ahead of print.
24. **Multimodal treatment for resectable neuroendocrine carcinoma of the cervix.** Valenza C, Spada F, Multinu F, Benini L, Borghesani M, Algeri L, Rubino M, Pisa E, Gervaso L, Cella CA, Carinelli S, Bruni S, Schivardi G, Curigliano G, Zanagnolo V, Aletti G, Colombo N, Fazio N. *Endocr Relat Cancer.* 2023 Jul 1;ERC-23-0112. doi: 10.1530/ERC-23-0112. Online ahead of print. PMID: 37428640
25. **Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists.** La Salvia A, Modica R, Rossi RE, Spada F, Rinzivillo M, Panzuto F, Faggiano A, Cinieri S, Fazio N. *Cancer Treat Rev.* 2023 Apr 17;117:102560. doi: 10.1016/j.ctrv.2023.102560. Online ahead of print. PMID: 37088017 Review.
26. **Can Ki-67 predict radiotherapy response in neuroendocrine tumors?**



CURRICULUM VITAE

- Retrospective analysis of a monocentric series of patients.** Zerini D, Rotondi M, Volpe S, Pisa E, Frigo E, Pedone C, Flospergher M, Bagnardi V, Frassoni S, Fodor CI, **Spada F**, Fazio N, Alterio D, Jereczek-Fossa BA. Tumori. 2023 Mar 20;3008916231160587. doi: 10.1177/03008916231160587. Online ahead of print.PMID: 36942401
- 27. Observational Study on Antibody Response to COVID-19 Vaccines in PATients with Gastro-Entero-PanCreactic Cancers and NeuroendocrIne NeoplAsms on Systemic TreatmEnts (VACCINATE).** Laffi A, Gervaso L, D'Ecclesiis O, Gandini S, Riva A, Passerini R, **Spada F**, Pellicori S, Rubino M, Cella CA, Ravenda PS, Zampino MG, Fazio N. Biomedicines. 2023 Jan 25;11(2):336. doi: 10.3390/biomedicines11020336.PMID: 36830873
- 28. Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer** Cella CA, Knoedler M, Hall M, Arcopinto M, Bagnardi V, Gervaso L, Pellicori S, **Spada F**, Zampino MG, Ravenda PS, Frassoni S, Passaro A, Milano M, Laffi A, Fazio N, Lordick F. JAMA Netw Open. 2023 Feb 1;6(2):e230010. doi: 10.1001/jamanetworkopen.2023.0010.PMID: 36795409
- 29. Metronomic chemotherapy in patients with advanced neuroendocrine tumors: A single-center retrospective analysis.** Arrivi G, **Spada F**, Frassoni S, Bagnardi V, Laffi A, Rubino M, Gervaso L, Fazio N. J Neuroendocrinol. 2022 Oct;34(10):e13189. doi: 10.1111/jne.13189. Epub 2022 Aug 16.PMID: 36306196
- 30. Nodal Merkel Cell Carcinoma with Unknown Primary Site and No Distant Metastasis: A Single-Center Series.** Fazio N, Maisonneuve P, **Spada F**, Gervaso L, Cella CA, Pozzari M, Zerini D, Pisa E, Fumagalli C, Barberis M, Laffi A, Grana C CM, Orsolini G, Prestianni P, Bonomo G, Funicelli L, Bertani E, Queirolo P, Ravizza D, Rubino M, Tosti G, Pennacchioli E. Cancers (Basel). 2022 Sep 29;14(19):4777. doi: 10.3390/cancers14194777
- 31. COVID-19 in patients with neuroendocrine neoplasms: two-year results of the INTENSIVE study.** Fazio N, Gervaso L, Halfdanarson TR, Sonbol M, Eiring RA, Pusceddu S, Prinzi N, Lombardi Stocchetti B, Grozinsky-Glasberg S, Gross DJ, Walter T, Robelin P, Lombard-Bohas C, Frassoni S, Bagnardi V, Antonuzzo L, Sparano C, Massironi S, Gelsomino F, Bongiovanni A, Ranallo N, Tafuto S, Rossi M, Cives M, Rasul KI, Hamid H, Chirco A, Squadroni M, La Salvia A, Hernando J, Hofland J, Koumarianou A, Boselli S, Tamayo D, Mazzon C, Rubino M, **Spada F**. Endocr Relat Cancer. 2023 Mar 1:ERC-22-0395. doi: 10.1530/ERC-22-0395.
- 32. Addressing the Role of Angiogenesis in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus: A Biological Prospective Analysis of Soluble Biomarkers and Clinical Outcomes.** Cella CA, **Spada F**, Berruti A, Bertolini F, Mancuso P, Barberis M, Pisa E, Rubino M, Gervaso L, Laffi A, Pellicori S, Radice D, Zorzino L, Calleri A, Funicelli L, Petralia G, Fazio N. Cancers (Basel). 2022 Sep 15;14(18):4471. doi: 10.3390/cancers14184471.PMID: 36139632
- 33. Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (carcinoid): Results from the Phase 2 ATLANT Study.** Ferolla P, Berruti A, **Spada F**, Brizzi



CURRICULUM VITAE

MP, Ibrahim T, Marconcini R, Giuffrida D, Amoroso V, La Salvia A, Vaccaro V, Faggiano A, Colao A, Volante M, Ghizzoni S, Mazzanti P, Houchard A, Fazio N. *Neuroendocrinology*. 2022 Aug 31. doi: 10.1159/000526811. Online ahead of print. PMID: 36044870

- 34. Metachronous Testicular Metastases from Merkel Cell Carcinoma (MCC): A Case Report and Literature Review.** Laffi A, Cozzi G, **Spada F**, Fazio N, Bertuzzi AF, Santoro A. *Am J Case Rep*. 2022 Aug 29;23:e936552. doi: 10.12659/AJCR.936552. PMID: 36031755
- 35. Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel.** **Spada F**, Bossi P, Caracò C, Sileni VC, Dei Tos AP, Fazio N, Grignani G, Maio M, Quaglino P, Queirolo P, Ascierto PA; DELPHI Panel Members. *J Immunother Cancer*. 2022 Jun;10(6):e004742. doi: 10.1136/jitc-2022-004742. PMID: 35701070
- 36. A Multinational Pilot Study on Patients' Perceptions of Advanced Neuroendocrine Neoplasms on the EORTC QLQ-C30 and EORTC QLQ-GINET21 Questionnaires.** van Leeuwen RS, González-Clavijo AM, Pracht M, Emelianova G, Cheung WY, Thirlwell C, Öberg K, **Spada F**. *J Clin Med*. 2022 Feb 25;11(5):1271. doi: 10.3390/jcm11051271. PMID: 35268362
- 37. Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside.** de Sousa MJ, Gervaso L, Meneses-Medina MI, **Spada F**, Abdel-Rahman O, Fazio N. *Curr Oncol Rep*. 2022 Jun;24(6):715-722. doi: 10.1007/s11912-022-01251-x. Epub 2022 Mar 9. PMID: 35262877
- 38. Predicting resectability of primary tumor and mesenteric lymph-node masses in patients with small-intestine neuroendocrine tumors.** Bertani E, Zugni F, Radice D, **Spada F**, Bonomo G, Fumagalli Romario U, Fazio N, Funicelli L. *Updates Surg*. 2022 Oct;74(5):1697-1704. doi: 10.1007/s13304-022-01251-3. Epub 2022 Feb 27. PMID: 35224681
- 39. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.** Pusceddu S, Prinzi N, Tafuto S, Ibrahim T, Filice A, Brizzi MP, Panzuto F, Baldari S, Grana CM, Campana D, Davì MV, Giuffrida D, Zatelli MC, Partelli S, Razzore P, Marconcini R, Massironi S, Gelsomino F, Faggiano A, Giannetta E, Bajetta E, Grimaldi F, Cives M, Cirillo F, Perfetti V, Corti F, Ricci C, Giacomelli L, Porcu L, Di Maio M, Seregni E, Maccauro M, Lastoria S, Bongiovanni A, Versari A, Persano I, Rinzivillo M, Pignata SA, Rocca PA, Lamberti G, Cingarlini S, Puliafito I, Ambrosio MR, Zanata I, Bracigliano A, Severi S, **Spada F**, Andreasi V, Modica R, Scalorbi F, Milione M, Sabella G, Coppa J, Casadei R, Di Bartolomeo M, Falconi M, de Braud F. *JAMA Netw Open*. 2022 Feb 1;5(2):e220290. doi: 10.1001/jamanetworkopen.2022.0290. PMID: 35201309
- 40. [177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective** **Spada F**, Campana D, Lamberti G, Laudicella R, Dellamano R, Dellamano L, Leeuwenkamp O, Baldari S. *Eur J Nucl Med Mol Imaging*. 2022 May;49(6):2037-2048. doi:



- 41. A Retrospective Analysis of the Correlation between Functional Imaging and Clinical Outcomes in Grade 3 Neuroendocrine Tumors (NETs G3).** Laffi A, Colandrea M, Buonsanti G, Frassoni S, Bagnardi V, **Spada F**, Pisa E, Barberis M, Rubino M, Grana CM, Ceci F, Fazio N. *Diagnostics (Basel)*. 2021 Dec 20;11(12):2401. doi: 10.3390/diagnostics11122401.PMID: 34943637
- 42. Ten years-experience of sunitinib in the treatment of advanced pan-NETs: an update on safety profile.** Vivanet G, Gervaso L, Laffi A, Rubino M, **Spada F**, Fazio N. *Expert Opin Drug Saf*. 2022 Mar;21(3):303-310. doi: 10.1080/14740338.2022.2000964. Epub 2021 Nov 12.PMID: 34724869
- 43. Corrigendum to 'Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study' [European Journal of Cancer 154 (2021) 246-252].** Fazio N, Gervaso L, Halfdanarson TR, La Salvia A, Hofland J, Hernando J, Sonbol MB, Garcia-Carbonero R, Capdevila J, de Herder WW, Koumarianou A, Kaltsas G, Rossi M, Grozinsky-Glasberg S, Oleinikov K, Boselli S, Tamayo D, Bagnardi V, Laffi A, Rubino M, **Spada F**. *Eur J Cancer*. 2022 Jan;160:289-290. doi: 10.1016/j.ejca.2021.10.001. Epub 2021 Oct 21.PMID: 34690038
- 44. Reply to comments on 'COVID-19 in patients with neuroendocrine neoplasms: Preliminary results of a worldwide survey (The INTENSIVE study)'** Fazio N, **Spada F**, Gervaso L. *Eur J Cancer*. 2021 Nov;157:531-532. doi: 10.1016/j.ejca.2021.08.021. Epub 2021 Aug 23.PMID: 34507830
- 45. Should temozolomide be used on the basis of O6-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and meta-analysis.** Trillo Aliaga P, **Spada F**, Peveri G, Bagnardi V, Fumagalli C, Laffi A, Rubino M, Gervaso L, Guerini Rocco E, Pisa E, Curigliano G, Fazio N. *Cancer Treat Rev*. 2021 Sep;99:102261. doi: 10.1016/j.ctrv.2021.102261. Epub 2021 Jul 22.PMID: 34332293
- 46. SARS-CoV-2-related pneumonia can be successfully managed in patients with metastatic neuroendocrine tumors: a critical point of view.** Spada F, Pellicori S, Zampino G, Funicelli L, Gervaso L, Laffi A, Rubino M, Garcia-Carbonero R, Fazio N. *Endocrine*. 2020 Oct;70(1):6-10. doi: 10.1007/s12020-020-02419-w. Epub 2020 Jul 17.PMID: 32681385
- 47. Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study.** Fazio N, Gervaso L, Halfdanarson TR, La Salvia A, Hofland J, Hernando J, Sonbol MB, Garcia-Carbonero R, Capdevila J, de Herder WW, Koumarianou A, Kaltsas G, Rossi M, Grozinsky-Glasberg S, Oleinikov K, Boselli S, Tamayo D, Bagnardi V, Laffi A, Rubino M, **Spada F**. *Eur J Cancer*. 2021 Sep;154:246-252. doi: 10.1016/j.ejca.2021.06.029. Epub 2021 Jun 30.PMID: 34298375
- 48. Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis.** Laffi A, **Spada F**, Bagnardi V, Frassoni S, Pisa E, Rubino M, Barberis M, Fazio N. *J Endocrinol Invest*. 2022 Feb;45(2):317-325. doi: 10.1007/s40618-021-01642-0. Epub 2021 Jul



- 49. Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience** Bardasi C, Spallanzani A, Benatti S, **Spada F**, Laffi A, Antonuzzo L, Lavacchi D, Marconcini R, Ferrari M, Rimini M, Caputo F, Santini C, Cerma K, Casadei-Gardini A, Andrikou K, Salati M, Bertolini F, Fontana A, Dominici M, Luppi G, Gelsomino F. *Endocrine*. 2021 Dec;74(3):707-713. doi: 10.1007/s12020-021-02813-y. Epub 2021 Jul 6. PMID: 34231124
- 50. Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management.** **Spada F**, Rossi RE, Kara E, Laffi A, Massironi S, Rubino M, Grimaldi F, Bhoori S, Fazio N. *Pharmaceuticals (Basel)*. 2021 Jun 4;14(6):539. doi: 10.3390/ph14060539. PMID: 34199977
- 51. Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours.** Dawod M, Gordo TA, Cives M, De Mestier L, Crona J, **Spada F**, Oberg K, Pavel M, Lamarca A. *Curr Treat Options Oncol*. 2021 Jun 29;22(8):73. doi: 10.1007/s11864-021-00863-y. PMID: 34185197
- 52. Looking for the right TNM staging system for pancreatic neuroendocrine tumors.** Fazio N, **Spada F**, Bertani E. *Hepatobiliary Surg Nutr*. 2021 Jun;10(3):382-384. doi: 10.21037/hbsn-2021-1. PMID: 34159169
- 53. Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs.** Lenotti E, Alberti A, Spada F, Amoroso V, Maisonneuve P, Grisanti S, Baggi A, Bianchi S, Fazio N, Berruti A. *Front Endocrinol (Lausanne)*. 2021 Apr 27;12:669484. doi: 10.3389/fendo.2021.669484. eCollection 2021. PMID: 33986731
- 54. Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509).** Capdevila J, Fazio N, Lopez C, Teulé A, Valle JW, Tafuto S, Custodio A, Reed N, Raderer M, Grande E, Garcia-Carbonero R, Jimenez-Fonseca P, Hernando J, Bongiovanni A, Spada F, Alonso V, Antonuzzo L, Spallanzani A, Berruti A, La Casta A, Sevilla I, Kump P, Giuffrida D, Merino X, Trejo L, Gajate P, Matos I, Lamarca A, Ibrahim T. *J Clin Oncol*. 2021 Jul 10;39(20):2304-2312. doi: 10.1200/JCO.20.03368. Epub 2021 May 4. PMID: 33945297
- 55. A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy.** A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy. Hasic Telalovic J, Pillozzi S, Fabbri R, Laffi A, Lavacchi D, Rossi V, Dreoni L, Spada F, Fazio N, Amedei A, Iadanza E, Antonuzzo L. *Diagnostics (Basel)*. 2021 Apr 28;11(5):804. doi: 10.3390/diagnostics11050804. PMID: 33925256
- 56. Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd-line treatment.** Lamarca A, Cives M, de Mestier L, Crona J, Spada F, Öberg K, Pavel M, Alonso-Gordo T. *World J Gastroenterol*. 2021 Mar 14;27(10):976-989. doi: 10.3748/wjg.v27.i10.976.



- 57. Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis.** Garcia-Torralba E, **Spada F**, Lim KHJ, Jacobs T, Barriuso J, Mansoor W, McNamara MG, Hubner RA, Manoharan P, Fazio N, Valle JW, Lamarca A. *Cancer Treat Review*. Mar;94:102168. doi: 10.1016/j.ctrv.2021.102168. Epub 2021 Feb 19. PMID: 33730627
- 58. The rare entity of bilateral and unilateral neuroendocrine metastases to the breast: a case series and literature review.** Zagami P, Kandaraki E, Renne G, Grimaldi F, **Spada F**, Laffi A, Fazio N. *Ecancermedicalscience*. 2020 Oct 15;14:1123.
- 59. Discussing motherhood when the oncological prognosis is dire: ethical considerations for physicians.** Linkeviciute A, Buonomo B, Fazio N, **Spada F**, Peccatori FA. *ESMO Open*. 2020 Nov;5(6):e000956.
- 60. Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms.** Rubino M, Scoazec JY, Pisa E, Faron M, Spaggiari L, Hadoux J, **Spada F**, Planchard D, Cella CA, Leboulleux S, De Marinis F, Ducreux M, Lamartina L, Baudin E, Fazio N. *Lung Cancer*. 2020 Oct;148:149-158.
- 61. Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet).** Panzuto F, Maccauro M, Campana D, Faggiano A, Massironi S, Pusceddu S, **Spada F**, Ferone D, Modica R, Grana CM, Ferolla P, Rinzivillo M, Badalamenti G, Zatelli MC, Gelsomino F, De Carlo E, Bartolomei M, Brizzi MP, Cingarlini S, Versari A, Fanciulli G, Arvat E, Merola E, Cives M, Tafuto S, Baldari S, Falconi M. *J Endocrinol Invest*. 2020 Aug 16:1-6.
- 62. Multidisciplinary team approach for Merkel cell carcinoma: the European Institute of Oncology experience with focus on radiotherapy.** Zerini D, Patti F, **Spada F**, Fazio N, Pisa E, Pennacchioli E, Prestianni P, Cambria R, Pepa M, Grana CM, Bonomo G, Funicelli L, Jereczek-Fossa BA, Orecchia R. *Tumori*. 2020 Jul 31:300891620944209.
- 63. Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis.** **Spada F**, Maisonneuve P, Fumagalli C, Marconcini R, Gelsomino F, Antonuzzo L, Campana D, Puliafito I, Rossi G, Faviana P, Messerini L, Barberis M, Fazio N. *Endocrine*. 2020 Jul 22.
- 64. Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors.** Fazio N, Cella CA, Del Re M, Laffi A, Rubino M, Zagami P, **Spada F**. *Expert Opin Drug Metab Toxicol*. 2019 Dec;15(12):993-1004.
- 65. Should platinum-based chemotherapy be preferred for germline BRCA1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.** Rebelatto TF, Falavigna M, Pozzari M, **Spada F**, Cella CA, Laffi A, Pellicori S, Fazio N. *Cancer Treat Rev*. 2019 Nov;80:101895.
- 66. Carboplatin in Combination with Oral or Intravenous Etoposide for Extra Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas.** Frizziero M, **Spada F**, Lamarca A, Kordatou Z, Barriuso J, Nuttall C, McNamara MG, Hubner



CURRICULUM VITAE

RA, Mansoor W, Manoharan P, Fazio N, Valle JW. *Neuroendocrinology*. 2019;109(2):100-112.

- 67. Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms.** Grimaldi F, Fazio N, Attanasio R, Frasoldati A, Papini E, Cremonini N, Davi MV, Funicelli L, Massironi S, Spada F, Toscano V, Versari A, Zini M, Falconi M, Oberg K. *Endocr Metab Immune Disord Drug Targets*. 2018;18(5):419-449.
- 68. Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis.** Pozzari M, Maisonneuve P, **Spada F**, Berruti A, Amoroso V, Cella CA, Laffi A, Pellicori S, Bertani E, Fazio N. *Cancer Treat Rev*. 2018 Dec;71:39-46.
- 69. Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM).** Dieci MV, Massari F, Giusti R, Inno A, Lombardi G, Noto L, Passaro A, Pietrantonio F, **Spada F**, Valente M, Di Maio M, Torri V. *ESMO Open*. 2018 Oct 21;3(6):e000389.
- 70. A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors.** Peri M, Botteri E, Pisa E, De Marinis F, Ungaro A, **Spada F**, Grana CM, Gasparri R, Spaggiari L, Romentz N, Badalamenti G, Russo A, Fazio N. *J Thorac Dis*. 2018 Jul;10(7):3928-3939.
- 71. Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study.** Brighi N, La Rosa S, Rossi G, Grillo F, Pusceddu S, Rinzivillo M, **Spada F**, Tafuto S, Massironi S, Faggiano A, Antonuzzo L, Santini D, Sessa F, Maragliano R, Gelsomino F, Albertelli M, Vernieri C, Panzuto F, Fazio N, De Divitiis C, Lamberti G, Colao A, Fave GD, Campana D. *Ann Surg*. 2018 Jul 10
- 72. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.** Pusceddu S, Vernieri C, Di Maio M, Marconcini R, **Spada F**, Massironi S, Ibrahim T, Brizzi MP, Campana D, Faggiano A, Giuffrida D, Rinzivillo M, Cingarlini S, Aroldi F, Antonuzzo L, Berardi R, Catena L, De Divitiis C, Ermacora P, Perfetti V, Fontana A, Razzore P, Carnaghi C, Davi MV, Cauchi C, Duro M, Ricci S, Fazio N, Cavalcoli F, Bongiovanni A, La Salvia A, Brighi N, Colao A, Puliafito I, Panzuto F, Ortolani S, Zaniboni A, Di Costanzo F, Torniai M, Bajetta E, Tafuto S, Garattini SK, Femia D, Prinzi N, Concas L, Lo Russo G, Milione M, Giacomelli L, Buzzoni R, Delle Fave G, Mazzaferro V, de Braud F. *Gastroenterology* 2018 Aug;155(2):479-489
- 73. A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors.** Pusceddu S, Barretta F, Trama A, Botta L, Milione M, Buzzoni R, de Braud F, Mazzaferro V, Pastorino U, Seregni E, Mariani L, Gatta G, Di Bartolomeo M, Femia D, Prinzi N, Coppa J, Panzuto F, Antonuzzo L, Bajetta E, Maria BP, Campana D, Catena L, Comber H, Dwane F, Fazio N, Faggiano A, Giuffrida D, Henau K, Ibrahim T, Marconcini R, Massironi S, Žakelj MP, **Spada F**, Tafuto S, Van



Eycken E, Van der Zwan JM, Žagar T, Giacomelli L, Miceli R. *Endocr Relat Cancer*. 2018 Mar 20.

- 74. Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study.** Rinzivillo M, Fazio N, Pusceddu S, Spallanzani A, Ibrahim T, Campana D, Marconicini R, Partelli S, Badalamenti G, Brizzi MP, Catena L, Schinzari G, Carnaghi C, Berardi R, Faggiano A, Antonuzzo L, **Spada F**, Gritti S, Femia D, Gelsomino F, Bongiovanni A, Ricci S, Brighi N, Falconi M, Delle Fave G, Panzuto F. *Pancreatology*. 2018 Mar;18(2):198-203.
- 75. Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms.** Grimaldi F, Fazio N, Attanasio R, Frasoldati A, Papini E, Cremonini N, Davi M, Funicelli L, Massironi S, **Spada F**, Toscano V, Versari A, Zini M, Falconi M, Oberg K. *Endocr Metab Immune Disord Drug Targets*. 2017 Dec 13.
- 76. The role of multimodal treatment in patients with advanced lung neuroendocrine tumors.** Fazio N, Ungaro A, **Spada F**, Cella CA, Pisa E, Barberis M, Grana C, Zerini D, Bertani E, Ribero D, Funicelli L, Bonomo G, Ravizza D, Guarize J, De Marinis F, Petrella F, Del Signore E, Pelosi G, Spaggiari L. *J Thorac Dis*. 2017 Nov;9(Suppl 15):S1501-S1510. Review.
- 77. Everolimus in Combination with Octreotide LAR in First Line Setting for Patients with Neuroendocrine Tumors: A 5-Years Update.** Bajetta E, Catena L, Pusceddu S, **Spada F**, Iannacone C, Sarno I, Di Menna G, Dottorini L, Marte AM. *Neuroendocrinology*. 2017 Jul 26.
- 78. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.** Martins D, **Spada F**, Lambrescu I, Rubino M, Cella C, Gibelli B, Grana C, Ribero D, Bertani E, Ravizza D, Bonomo G, Funicelli L, Pisa E, Zerini D, Fazio N; IEO ENETS Center of Excellence for GEP NETs. *Target Oncol*. 2017 Jun 21. [Epub ahead of print].
- 79. Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors.** Berardi R, Torniai M, Pusceddu S, **Spada F**, Ibrahim T, Brizzi MP, Antonuzzo L, Ferolla P, Panzuto F, Silvestris N, Partelli S, Ferretti B, Freddari F, Gucciardino C, Testa E, Concas L, Murgioni S, Bongiovanni A, Zichi C, Riva N, Rinzivillo M, Brunetti O, Giustini L, Di Costanzo F, Delle Fave G, Fazio N, De Braud F, Falconi M, Cascinu S. *Cancer Med*. 2017 Jul;6(7):1493-1499.
- 80. Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors.** Antonuzzo L, Del Re M, Barucca V, **Spada F**, Meoni G, Restante G, Danesi R, Di Costanzo F, Fazio N. *Cancer Treat Rev*. 2017 Jun;57:28-35.
- 81. Metronomic and metronomic-like therapies in neuroendocrine tumors - Rationale and clinical perspectives.** Lambrescu I, Fica S, Martins D, **Spada F**, Cella C, Bertani E, Rubino M, Gibelli B, Grana C, Bonomo G, Funicelli L, Ravizza D, Pisa E, Zerini D, Ungaro A, Fazio N; IEO ENETS Center of Excellence for GEP NET. *Cancer Treat Rev*. 2017 Apr;55:46-56.
- 82. When Should Everolimus Be Administered in the Natural History of Pancreatic Neuroendocrine Tumors?** Amoroso V, Fazio N, Mosca A, Roca E, **Spada F**, Foroni C, Agazzi GM, Berruti A. *J Clin Oncol*. 2017 May 1;35(13):1487-1488.



- 83. Everolimus in Pancreatic Neuroendocrine Carcinomas G3.** Panzuto F, Rinzivillo M, **Spada F**, Antonuzzo L, Ibrahim T, Campana D, Fazio N, Delle Fave G. *Pancreas*. 2017 Mar;46(3):302-305.
- 84. Regression of advanced neuroendocrine tumors among patients receiving placebo.** Amoroso V, Agazzi GM, Roca E, Fazio N, Mosca A, Ravanelli M, **Spada F**, Maroldi R, Berruti A. *Endocr Relat Cancer*. 2017 Feb;24(2):L13-L16.
- 85. Resection of the primary tumor followed by peptide receptor radionuclide therapy as upfront strategy for the treatment of G1-G2 pancreatic neuroendocrine tumors with unresectable liver metastases.** Bertani E, Fazio N, Radice D, Zardini C, Grana C, Bodei L, Funicelli L, Ferrari C, **Spada F**, Partelli S, Falconi M. *Ann Surg Oncol*. 2016 Sep 9.
- 86. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories.** Milione M, Maisonneuve P, **Spada F**, Pellegrinelli A, Spaggiari P, Albarello L, Pisa E, Barberis M, Vanoli A, Buzzoni R, Pusceddu S, Concas L, Sessa F, Solcia E, Capella C, Fazio N, La Rosa S. *Neuroendocrinology*. 2016 Mar 5.
- 87. Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors.** **Spada F**, Antonuzzo L, Marconcini R, Radice D, Antonuzzo A, Ricci S, Di Costanzo F, Fontana A, Gelsomino F, Luppi G, Nobili E, Galdy S, Cella CA, Sonzogni A, Pisa E, Barberis M, Fazio N. *Neuroendocrinology*. 2016 Jan 21.
- 88. Histologically-Proven Efficacy of Bland Embolization in a Patient with Net Liver Metastasis.** Monfardini L, Varano GM, Foà R, Della Vigna P, Bonomo G, Bertani E, Guerini-Rocco E, **Spada F**, Orsi F. *Cardiovasc Intervent Radiol*. 2016 Jun;39(6):948-52.
- 89. Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trials.** Galdy S, Cella CA, **Spada F**, Murgioni S, Frezza AM, Ravenda SP, Zampino MG, Fazio N. *Crit Rev Oncol Hematol*. 2016 Mar;99:1-12.
- 90. Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study.** Rinzivillo M, Capurso G, Campana D, Fazio N, Panzuto F, **Spada F**, Cicchese N, Partelli S, Tomassetti P, Falconi M, Delle Fave G. *Neuroendocrinology*. 2016;103(5):531-7.
- 91. Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: from bench to bedside.** Cella CA, Minucci S, **Spada F**, Galdy S, Elgendy M, Ravenda PS, Zampino MG, Murgioni S, Fazio N. *Cancer Treat Rev*. 2015 Nov;41(9):754-60.
- 92. Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: Prognostic factors for decision making.** Bertani E, Falconi M, Grana C, Botteri E, Chiappa A, Misitano P, **Spada F**, Ravizza D, Bazolli B, Fazio N. *Int J Surg*. 2015 Aug;20:58-64.



- 93. Real-world study of everolimus in advanced progressive neuroendocrine tumors.** Panzuto F, Rinzivillo M, Fazio N, de Braud F, Luppi G, Zatelli MC, Lugli F, Tomassetti P, Riccardi F, Nuzzo C, Brizzi MP, Faggiano A, Zaniboni A, Nobili E, Pastorelli D, Cascinu S, Merlano M, Chiara S, Antonuzzo L, Funaioli C, **Spada F**, Pusceddu S, Fontana A, Ambrosio MR, Cassano A, Campana D, Carteni G, Appetecchia M, Berruti A, Colao A, Falconi M, Delle Fave G. *Oncologist*. 2015 May;20(5):570.
- 94. Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.** Koumarianou A, Kaltsas G, Kulke MH, Oberg K, Strosberg JR, **Spada F**, Galdy S, Barberis M, Fumagalli C, Berruti A, Fazio N. *Neuroendocrinology*. 2015;101(4):274-88.
- 95. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: An ITMO group study.** Bajetta E, Catena L, Fazio N, Pusceddu S, Biondani P, Blanco G, Ricci S, Aieta M, Pucci F, Valente M, Bianco N, Mauri CM, **Spada F**. *Cancer*. 2014 Apr 18.
- 96. Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: Possible indications for a multimodal approach.** Bertani E, Fazio N, Botteri E, Chiappa A, Falconi M, Grana C, Bodei L, Papis D, **Spada F**, Bazolli B, Andreoni B. *Surgery*. 2014 Apr;155(4):607-14.
- 97. RAF signaling in neuroendocrine neoplasms: from bench to bedside.** Fazio N, Abdel-Rahman O, **Spada F**, Galdy S, De Dosso S, Capdevila J, Scarpa A. *Cancer Treat Rev*. 2014 Sep;40(8):974-9.
- 98. Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view.** Fazio N, **Spada F**, Giovannini M. *Cancer Treat Rev*. 2013 May; 39(3):270-4.
- 99. Hepatic intra-arterial chemotherapy in patients with advanced primary liver tumors.** **Spada F**, Fazio N, Bonomo G, Monfardini L, Della Vigna P, Radice D, Boselli S, Orsi F. *Ecancermedalscience* 2012;6:280.
- 100. Clinical response after sorafenib for hepatocellular carcinoma in elderly patients: a report of two cases.** **Spada F**, Squadroni M, Lorizzo K, Farris A, Fazio N. *Tumori*. 2012 Mar;98(2):53e-6e3.
- 101. Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.** Giuseppe Cabibbo, Emanuela Rolle, Massimo De Giorgio, Chiara Genco, Tiziana Pressiani, **Francesca Spada**, and Rodolfo Sacco; on behalf of the HCC Working Group. *Expert Rev. Anticancer Ther*. 11(12) 2011.
- 102. Neuroendocrine tumour arising inside a retrorectal tailgut cyst: report of two cases and a review of the literature.** **Francesca Spada**, Giuseppe Pelosi, Associate Professor; Michela Squadroni, MD; Antonio Farris, Ordinary Professor; Filippo de Braud, MD, and Nicola Fazio, MD. *Ecancermedalscience* 2011, 5:201
- 103. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.** Fazio N, Cinieri S, Lorizzo K, Squadroni M, Orlando L, **Spada F**, Maiello E, Bodei L, Paganelli G, Delle Fave G, de Braud F. *Cancer Treat Rev*. 2010 Nov;36S3:S87-S94.



CURRICULUM VITAE

- 104. Pancreatic neuroendocrine tumors: a focus on the current classification and molecular targeted therapy.** Michela Squadroni, Vincenzo Formica, Giovanni Di Meglio, Cristina Dealis, **Francesca Spada**, Katia Lorizzo and Nicola Fazio . Eur. J. of Clin Onc. Jul 2010

La sottoscritta Francesca Spada, nata ad Oristano il 06/11/1977, consapevole che, ai sensi dell'art. 76 del DPR 445/2000, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali vigenti in materia dichiara ai sensi degli art. 46 e 47 D.P.R. 445/2000 che quanto contenuto nel presente curriculum corrisponde a verità. Esprimo il mio consenso al trattamento dei dati sopra riportati, ai sensi del D. Lgs. 196/2003.

Iscrizione Ordine dei Medici di Oristano (n.993)

Francesca Spada

Milano lì, 25/04/2025